Clinical roundtable monograph. T-cell lymphoma

therapeutic overview and disease state awareness.

James Olen Armitage, Eric D. Hsi, Francine M. Foss

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

T-cell lymphomas comprise a heterogeneous group of lymphoproliferative disorders that include approximately 10-15% of all lymphomas, and there is a geographic variation in their frequency. With the exception of a few subtypes that are associated with a more indolent course, the majority of T-cell lymphomas are aggressive in nature. Patients with peripheral T-cell lymphomas (PTCL) have an especially poor prognosis, due both to the aggressive disease course as well as the lack of effective treatments. A number of PTCL subtypes have now been defined, although the histologic, immunologic, and cytogenetic distinctions between some subtypes are subtle. Proper diagnosis of the PTCL subtype is important, as each subtype is associated with a varying prognosis and thus may be treated differently. There is no true standard of care for PTCL, and this aggressive disease has historically been treated with therapeutic regimens designed for B-cell lymphomas, such as the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen. However, studies now show that these regimens are not optimal for most patients with PTCL. Therefore, recent efforts have focused on the development of therapeutic regimens designed to be more effective in PTCL, some of which are specifically targeted against T-cell markers. A number of these agents now show promise in the treatment of both frontline and relapsed/ refractory disease.

Original languageEnglish (US)
Pages (from-to)1-15
Number of pages15
JournalClinical advances in hematology & oncology : H&O
Volume8
Issue number12 Suppl 22
StatePublished - Dec 1 2010

Fingerprint

Peripheral T-Cell Lymphoma
T-Cell Lymphoma
Therapeutics
Lymphoproliferative Disorders
Vincristine
B-Cell Lymphoma
Standard of Care
Prednisone
Cytogenetics
Doxorubicin
Cyclophosphamide
Lymphoma
T-Lymphocytes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Clinical roundtable monograph. T-cell lymphoma : therapeutic overview and disease state awareness. / Armitage, James Olen; Hsi, Eric D.; Foss, Francine M.

In: Clinical advances in hematology & oncology : H&O, Vol. 8, No. 12 Suppl 22, 01.12.2010, p. 1-15.

Research output: Contribution to journalReview article

@article{7eb90db94ecc4098bc74fb5d967ea62c,
title = "Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness.",
abstract = "T-cell lymphomas comprise a heterogeneous group of lymphoproliferative disorders that include approximately 10-15{\%} of all lymphomas, and there is a geographic variation in their frequency. With the exception of a few subtypes that are associated with a more indolent course, the majority of T-cell lymphomas are aggressive in nature. Patients with peripheral T-cell lymphomas (PTCL) have an especially poor prognosis, due both to the aggressive disease course as well as the lack of effective treatments. A number of PTCL subtypes have now been defined, although the histologic, immunologic, and cytogenetic distinctions between some subtypes are subtle. Proper diagnosis of the PTCL subtype is important, as each subtype is associated with a varying prognosis and thus may be treated differently. There is no true standard of care for PTCL, and this aggressive disease has historically been treated with therapeutic regimens designed for B-cell lymphomas, such as the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen. However, studies now show that these regimens are not optimal for most patients with PTCL. Therefore, recent efforts have focused on the development of therapeutic regimens designed to be more effective in PTCL, some of which are specifically targeted against T-cell markers. A number of these agents now show promise in the treatment of both frontline and relapsed/ refractory disease.",
author = "Armitage, {James Olen} and Hsi, {Eric D.} and Foss, {Francine M.}",
year = "2010",
month = "12",
day = "1",
language = "English (US)",
volume = "8",
pages = "1--15",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "12 Suppl 22",

}

TY - JOUR

T1 - Clinical roundtable monograph. T-cell lymphoma

T2 - therapeutic overview and disease state awareness.

AU - Armitage, James Olen

AU - Hsi, Eric D.

AU - Foss, Francine M.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - T-cell lymphomas comprise a heterogeneous group of lymphoproliferative disorders that include approximately 10-15% of all lymphomas, and there is a geographic variation in their frequency. With the exception of a few subtypes that are associated with a more indolent course, the majority of T-cell lymphomas are aggressive in nature. Patients with peripheral T-cell lymphomas (PTCL) have an especially poor prognosis, due both to the aggressive disease course as well as the lack of effective treatments. A number of PTCL subtypes have now been defined, although the histologic, immunologic, and cytogenetic distinctions between some subtypes are subtle. Proper diagnosis of the PTCL subtype is important, as each subtype is associated with a varying prognosis and thus may be treated differently. There is no true standard of care for PTCL, and this aggressive disease has historically been treated with therapeutic regimens designed for B-cell lymphomas, such as the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen. However, studies now show that these regimens are not optimal for most patients with PTCL. Therefore, recent efforts have focused on the development of therapeutic regimens designed to be more effective in PTCL, some of which are specifically targeted against T-cell markers. A number of these agents now show promise in the treatment of both frontline and relapsed/ refractory disease.

AB - T-cell lymphomas comprise a heterogeneous group of lymphoproliferative disorders that include approximately 10-15% of all lymphomas, and there is a geographic variation in their frequency. With the exception of a few subtypes that are associated with a more indolent course, the majority of T-cell lymphomas are aggressive in nature. Patients with peripheral T-cell lymphomas (PTCL) have an especially poor prognosis, due both to the aggressive disease course as well as the lack of effective treatments. A number of PTCL subtypes have now been defined, although the histologic, immunologic, and cytogenetic distinctions between some subtypes are subtle. Proper diagnosis of the PTCL subtype is important, as each subtype is associated with a varying prognosis and thus may be treated differently. There is no true standard of care for PTCL, and this aggressive disease has historically been treated with therapeutic regimens designed for B-cell lymphomas, such as the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen. However, studies now show that these regimens are not optimal for most patients with PTCL. Therefore, recent efforts have focused on the development of therapeutic regimens designed to be more effective in PTCL, some of which are specifically targeted against T-cell markers. A number of these agents now show promise in the treatment of both frontline and relapsed/ refractory disease.

UR - http://www.scopus.com/inward/record.url?scp=80054115788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054115788&partnerID=8YFLogxK

M3 - Review article

VL - 8

SP - 1

EP - 15

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 12 Suppl 22

ER -